The Development Process for Discovery and Clinical Advancement of Modern Antimalarials
Trent D Ashton, Shane M Devine, Jorg J Mohrle, Benoit Laleu, Jeremy N Burrows, Susan A Charman, Darren J Creek, Brad E Sleebs
JOURNAL OF MEDICINAL CHEMISTRY | AMER CHEMICAL SOC | Published : 2019
Malaria is a devastating disease caused by Plasmodium parasites, resulting in approximately 435000 deaths in 2018. The impact of malaria is compounded by the emergence of widespread resistance to current antimalarial therapies. Recently, a new strategy was initiated to screen small molecule collections against the Plasmodium parasite enabling the identification of new antimalarial chemotypes with novel modes of action. This initiative ushered in the modern era of antimalarial drug development, and as a result, numerous lead candidates are advancing toward or are currently in human clinical trials. In this Perspective, we describe the development pathway of four of the most clinically advance..View full abstract
Related Projects (1)
Awarded by National Health and Medical Research Council of Australia
This work was supported by the National Health and Medical Research Council of Australia (development grant 1113712 to B.E.S.; fellowship 1148700 to D.J.C.; project grant 1163235 to D.J.C. and S.M.D.), Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. B.E.S. is a Corin Centenary Fellow.